{"id":55889,"date":"2026-01-30T12:54:17","date_gmt":"2026-01-30T04:54:17","guid":{"rendered":"https:\/\/flcube.com\/?p=55889"},"modified":"2026-01-30T12:54:18","modified_gmt":"2026-01-30T04:54:18","slug":"tyligand-bio-files-hong-kong-ipo-with-phase-ii-kras-g12d-inhibitor-tsn1611","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55889","title":{"rendered":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611"},"content":{"rendered":"\n<p><strong>Tyligand Bioscience Ltd.<\/strong> this week submitted its initial public offering (IPO) filing to the <strong>Hong Kong Stock Exchange<\/strong>. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product <strong>TSN1611<\/strong>, an oral <strong>KRAS G12D inhibitor<\/strong> currently in <strong>Phase II<\/strong> clinical trials.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile-amp-ipo-details\">Company Profile &amp; IPO Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Tyligand Bioscience Ltd.<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2017<\/td><\/tr><tr><td><strong>IPO Venue<\/strong><\/td><td>Hong Kong Stock Exchange (HKSE)<\/td><\/tr><tr><td><strong>Focus<\/strong><\/td><td>Innovative oncology therapies<\/td><\/tr><tr><td><strong>Pipeline<\/strong><\/td><td>4 drug candidates (2 clinical, 2 preclinical)<\/td><\/tr><tr><td><strong>Core Product<\/strong><\/td><td>TSN1611 (oral KRAS G12D inhibitor)<\/td><\/tr><tr><td><strong>TSN1611 Stage<\/strong><\/td><td>Phase\u202fII clinical trials<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>KRAS inhibition, STING agonism, ADC platforms<\/td><\/tr><tr><td><strong>Market Position<\/strong><\/td><td>Next\u2011generation targeted oncology pipeline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-overview\">Pipeline Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug Candidate<\/th><th>Target\/Mechanism<\/th><th>Stage<\/th><th>Indication Focus<\/th><\/tr><\/thead><tbody><tr><td><strong>TSN1611<\/strong><\/td><td>KRAS G12D inhibitor<\/td><td>Phase\u202fII<\/td><td>Solid tumors<\/td><\/tr><tr><td><strong>TSN222<\/strong><\/td><td>STING agonist<\/td><td>Phase\u202fI<\/td><td>Oncology<\/td><\/tr><tr><td><strong>TSNA1789<\/strong><\/td><td>STING\u2011agonist ADC (immunostimulatory)<\/td><td>Preclinical<\/td><td>Oncology<\/td><\/tr><tr><td><strong>TSNA3339<\/strong><\/td><td>EGFR\u2011KRAS G12D ADC<\/td><td>Preclinical<\/td><td>Oncology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-product-profile-tsn1611\">Core Product Profile: TSN1611<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Allosteric inhibitor specifically targeting <strong>KRAS G12D<\/strong>, one of the most common oncogenic mutations in pancreatic, colorectal, and lung cancers<\/li>\n\n\n\n<li><strong>Clinical Progress:<\/strong> Phase\u202fII trials underway; addresses <strong>~40,000 patients annually<\/strong> in China with G12D\u2011mutated tumors<\/li>\n\n\n\n<li><strong>Competitive Edge:<\/strong> Among <strong>few KRAS G12D inhibitors<\/strong> in clinical development; potential first\u2011in\u2011class or best\u2011in\u2011class opportunity<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> KRAS G12D historically considered &#8220;undruggable&#8221;; successful development would fill major unmet need<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>KRAS Inhibitor Market:<\/strong> Global market projected to exceed <strong>$5\u202fbillion<\/strong> :by 2030 if clinically validated; G12D segment represents <strong>30%<\/strong> of all KRAS mutations<\/li>\n\n\n\n<li><strong>IPO Valuation:<\/strong> Analysts estimate <strong>$200\u2013350\u202fmillion<\/strong> pre\u2011money valuation based on pipeline novelty and clinical progress<\/li>\n\n\n\n<li><strong>Use of Proceeds:<\/strong> Funds expected to advance TSN1611 through Phase\u202fII\/III, expand STING agonist platform, and build commercial manufacturing capabilities<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> Positions Tyligand as leader in next\u2011generation KRAS therapeutics; ADC platform offers additional pipeline depth<\/li>\n\n\n\n<li><strong>China Advantage:<\/strong> Domestic KRAS inhibitor development aligns with China\u2019s &#8220;innovation\u2011first&#8221; regulatory policy and NRDL reimbursement pathway<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fII data readout expected <strong>H2\u202f2027<\/strong> ; IPO pricing and trading debut targeted for <strong>Q2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Tyligand Bio\u2019s IPO timeline, clinical development, and market potential. Actual results may differ due to market conditions, clinical trial outcomes, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012901617_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of sehk26012901617_c.\"><\/object><a id=\"wp-block-file--media-827f0f33-f57e-42df-b652-6453094f600a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012901617_c.pdf\">sehk26012901617_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/sehk26012901617_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-827f0f33-f57e-42df-b652-6453094f600a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55893,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,72,4584],"class_list":["post-55889","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-ipo","tag-tyligand-bioscience"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55889\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611\" \/>\n<meta property=\"og:description\" content=\"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55889\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T04:54:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T04:54:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611\",\"datePublished\":\"2026-01-30T04:54:17+00:00\",\"dateModified\":\"2026-01-30T04:54:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889\"},\"wordCount\":397,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3006.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"IPO\",\"Tyligand Bioscience\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55889#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55889\",\"name\":\"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3006.webp\",\"datePublished\":\"2026-01-30T04:54:17+00:00\",\"dateModified\":\"2026-01-30T04:54:18+00:00\",\"description\":\"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55889\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3006.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3006.webp\",\"width\":1080,\"height\":608,\"caption\":\"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55889#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611 - Insight, China&#039;s Pharmaceutical Industry","description":"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55889","og_locale":"en_US","og_type":"article","og_title":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611","og_description":"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.","og_url":"https:\/\/flcube.com\/?p=55889","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T04:54:17+00:00","article_modified_time":"2026-01-30T04:54:18+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55889#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55889"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611","datePublished":"2026-01-30T04:54:17+00:00","dateModified":"2026-01-30T04:54:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55889"},"wordCount":397,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55889#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","keywords":["ADC \/ XDC","IPO","Tyligand Bioscience"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55889#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55889","url":"https:\/\/flcube.com\/?p=55889","name":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55889#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55889#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","datePublished":"2026-01-30T04:54:17+00:00","dateModified":"2026-01-30T04:54:18+00:00","description":"Tyligand Bioscience Ltd. this week submitted its initial public offering (IPO) filing to the Hong Kong Stock Exchange. Founded in 2017, the biopharmaceutical company is dedicated to discovering and developing innovative oncology therapies, with a pipeline comprising four drug candidates led by its core product TSN1611, an oral KRAS G12D inhibitor currently in Phase II clinical trials.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55889#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55889"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55889#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","width":1080,"height":608,"caption":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55889#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3006.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55889","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55889"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55889\/revisions"}],"predecessor-version":[{"id":55894,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55889\/revisions\/55894"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55893"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55889"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55889"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55889"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}